Express Scripts says Praluent, Repatha will not be "budget busters"

Sept 30 (Reuters) - Express Scripts Holding Co said on Wednesday two costly new potent cholesterol fighters will not be "budget busters" for its clients and that most prescriptions for the drugs have been rejected because patients did not meet required medical criteria.